# OnCo record paper-rohaas-til-vs-ipilimumab-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-rohaas-til-vs-ipilimumab-nejm-2022" ;
schema:name "Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma"@en ;
schema:description "In a head-to-head trial, tumour-infiltrating lymphocyte therapy halved the risk of progression compared with ipilimumab in melanoma that had mostly already failed PD-1 blockade."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , ;
schema:sameAs ;
schema:datePublished "2022"^^xsd:gYear ;
schema:author "Rohaas MW, Borch TH, van den Berg JH, et al." ;
onco:related ;
onco:cancers ;
onco:technologies ;
onco:targets ;
onco:drugs , , , ;
onco:institutions ;
onco:terms , ;
onco:people , ;
onco:bottlenecks , ;
onco:journals .